Mycophenolate vs Azathioprin in Autoimmune Hepatitis
Phase 4
Completed
- Conditions
- Autoimmune Hepatitis
- Interventions
- Drug: Treatment with mycophenolat mofetilDrug: Treatment with azathioprin
- Registration Number
- NCT00687180
- Lead Sponsor
- Rigshospitalet, Denmark
- Brief Summary
A study with 20 de novo patients with autoimmune hepatitis, 10 receiving azathioprin and 10 receiving mycophenolat mofetil.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- De novo autoimmune hepatitis
- Consent
Exclusion Criteria
- age below 18
- pregnancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description I Treatment with mycophenolat mofetil MMF II Treatment with azathioprin -
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of mycophenolate mofetil in autoimmune hepatitis treatment?
How does azathioprine compare to mycophenolate mofetil in autoimmune hepatitis clinical outcomes?
Which biomarkers predict response to mycophenolate mofetil in autoimmune hepatitis patients?
What are the adverse event profiles of mycophenolate mofetil versus azathioprine in autoimmune hepatitis?
Are there combination therapies involving mycophenolate mofetil for autoimmune hepatitis treatment?
Trial Locations
- Locations (1)
Rigshospitalet, Dept. of Hepatology A-2121
🇩🇰Copenhagen, Denmark
Rigshospitalet, Dept. of Hepatology A-2121🇩🇰Copenhagen, Denmark